BCL2 and malignant colon neoplasm: The combination of GRh2 and L-OHP reversed oxaliplatin resistance in LoVo/L-OHP colon cancer cells by down-regulating the expression of P-gp and Bcl-2, and up-regulating the expression levels of Smad4, Bax, and caspase-3, and regulating the expression of drug resistance genes (Ma H et al., 2019).